Anixa Biosciences’ (ANIX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report sent to investors on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $10.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th.

Anixa Biosciences Price Performance

NASDAQ ANIX opened at $2.82 on Wednesday. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.79. The company has a market capitalization of $90.80 million, a P/E ratio of -7.23 and a beta of 0.90. The company’s 50 day simple moving average is $2.76 and its 200 day simple moving average is $3.04.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. On average, analysts anticipate that Anixa Biosciences will post -0.46 earnings per share for the current year.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the transaction, the director now owns 922,334 shares of the company’s stock, valued at $2,370,398.38. The trade was a 1.10 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Amit Kumar bought 43,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the acquisition, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 68,289 shares of company stock worth $157,101. 22.60% of the stock is owned by corporate insiders.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently made changes to their positions in the stock. International Assets Investment Management LLC lifted its position in Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after buying an additional 23,800 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences in the third quarter worth $34,000. Westside Investment Management Inc. raised its holdings in shares of Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares in the last quarter. Finally, Tyler Stone Wealth Management raised its holdings in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after acquiring an additional 21,008 shares in the last quarter. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.